54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera
Read MoreOral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)
IND enabling studies underway, with Phase I initiation expected in Q425
Webcast and conference call to be held today at 4:30 pm ET
Read More